The PROSUME Energy Foundation Presents a Blockchain-Based Platform That Will Foster the Peer-to-Peer Energy Exchanges
Rethinking the actual energy models, looking forward a network of communities and new ways to share sources: these are the ideas behind the Swiss PROSUME Energy Foundation, founded in Zug, the heart of the Crypto Valley, by professionals with a strong and long-time experience in the energy sector as well as in the blockchain softwares.
The Foundation has developed a new revolutionary platform to exchange electricity from renewable and fossil sources. It connects independent power producers, consumers, innovative utility companies and energy communities in a locally shared market where each peer is free to interact in a multi-tenant ecosystem.
The mission of the Foundation is to promote decentralizing power models and empower energy communities through the blockchain software technology and through the implementation of peer to peer energy exchange policies targeting possible solutions for all the existing physical and legal energy framework barriers, investing in Research & Development to offer innovative hardware and IoT-devices related to smart metering, smart grid, energy routers and devices.
PROSUME is based over 3 main pillars: decentralization, digitalization and decarbonisation. Blockchain has been considered the perfect tool to achieve the mission of the Foundation because this disruptive technology combines IT with cryptography and governance principles to create a new safer, more resilient and transparent place where everyone could be independent in choosing his own energy sources.
In order to support its project and mission, Prosume is launching a pre-ICO based on upgradeable ERC20 derivate Token named PEF Token on the Ethereum platform, the industry standard for issuing custom digital assets and smart contracts. Its ease in the use by everyone let Ethereum be the perfect solution for an Initial Coin Offering.
Because the platform deals with many of today’s problems and opportunities related to the energy sharing sector, like support for regulation frameworks, fair policy pricing, network balancing, smart payment and smart billing, the advanced features and active ecosystem of Ethereum make it the natural fit for Prosume. Ethereum’s ability to deploy smart contracts enables complex issuance rules for cryptocurrencies, digital financial contracts, and automated incentive structures.
“We strongly believe in the sharing energy model based on the peer to peer exchange system, for this reason PROSUME platform has as its main goal to be the most innovative place to develop energy communities, in order to give everyone the possibility to exchange energy in a more transparent, traceable, accessible, flexible, resilient and sustainable way” affirms Alfredo Giardina, Co-founder of PROSUME Energy Foundation.
The pre-ICO will start on the 27th of September 2017, providing early
adopters and strategic partners the chance to exchange tokens for
ETH or BTC or LTC with a significant Bonus, starting at 47 %.
The main ICO will last for 4 weeks, with a different bonus rate every week limited to a certain size.
The ERC20 token interface allows for the deployment of a standard token that is compatible with the existing infrastructure of the Ethereum ecosystem, such as development tools, wallets, and exchanges.
The token accepted for the pre-ICO are ETH (ethereum) BTC (bitcoin) and LTC (litecoin).
The PEF Token will be upgradeable using an opt-in mechanism for future upgrades and it will be non-transferable until the ICO ends. The ICO contract will have a limit of 50000 PEF Tokens in order to facilitate a uniform ICO process. Multiple transactions are allowed.
“Several energy companies from all around Europe have already showed a keen interest in this project and PROSUME is now negotiating eight different pilot projects. The upcoming pre-ICO will be the perfect opportunity to let everyone take active part to this great revolution. We really do believe in the power of sharing energy as this is the best way to empower yourself and gain your independence” continues Mr. Giardina.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Andersen Global Expands Presence in Germany with Addition of Thierhoff Müller & Partner13.12.2017 08:01 | Pressemelding
Andersen Global is proud to announce an expanded presence in Germany as Thierhoff Müller & Partner, a tax and legal firm with offices in Leipzig and Frankfurt, combines its practice with Andersen Tax & Legal in Germany. Through its German member firms, Andersen Tax & Legal and Alegis Steuerberatungsgesellschaft mbH, Andersen Global now has more than 65 professionals focused on providing tax and legal services and business advice across five locations in Germany, including Cologne, Dusseldorf, and Merzig. “Thierhoff Müller is highly regarded in complex restructuring matters. Together with our existing legal and tax practice, we will be able to increase our service offerings for our clients,” said Stefan Kraus, Managing Partner of Andersen Tax & Legal in Germany. “We are dedicated to providing outstanding service and are adding additional competencies in tax and legal such as corporate r
Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs13.12.2017 08:00 | Pressemelding
Aprecia Pharmaceuticals, LLC (“Aprecia”), The 3DP Pharmaceutical Company, and Cycle Pharmaceuticals, Ltd. (“Cycle”) today announced they have signed a partnership agreement to develop and commercialize orphan drugs using three-dimensionally printed (“3DP”) technology. The planned products will deliver quality-of-life improvements versus existing, approved orphan drugs, and will achieve this by utilizing Aprecia’s proprietary 3DP ZipDose® Technology platform. ZipDose® is the only three-dimensional printing technology used in a pharmaceutical drug product approved by the U.S. Food and Drug Administration. Antonio Benedetti, CEO of Cycle commented: “Many rare disease patients do not have a treatment option at all. For those rare diseases where there is an approved pharmaceutical treatment, patients continue to be burdened by sub-optimal drug formulations. Aprecia’s
Group Vivendi Africa Deploys Netcracker OSS to Enhance Service Management as it Expands Across the Continent12.12.2017 16:07 | Pressemelding
Netcracker Technology announced today that its OSS suite was selected and deployed to support the long-term growth strategy of Group Vivendi Africa (GVA). GVA is a newly formed affiliate of the French-based multinational conglomerate Vivendi with the goal to deploy and operate a fiber network across Africa. Netcracker's OSS will be used as a consolidated solution to identify service availability across GVA's operating countries and then fulfill and provision those services to customers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005937/en/ Netcracker's highly productized, out-of-the-box applications enabled the OSS suite to be deployed in seven months, meeting GVA's demand to leverage an integrated service fulfillment and inventory solution that could satisfy its long-term growth expectations, as well as s
Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program12.12.2017 15:23 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today released its latest Scientific Update for Smoke-Free Products, a regular publication on its research efforts to develop and assess a range of smoke-free alternatives to cigarettes. The latest issue of the Scientific Update can be found at this link. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171212005891/en/ Philip Morris International Releases Latest Scientific Update for Smoke-Free Products on Clinical Program (Photo: Business Wire) This issue of the Scientific Update provides a closer look at some of the principles and practices on which PMI’s scientific assessment program is built. Director Medical Affairs Dr. Patrick Picavet describes specific examples from PMI’s clinical program that highlight the company’s
Murex to Offer MX.3 Risk, Trading and Post-Trade Solutions on the AWS Cloud12.12.2017 14:00 | Pressemelding
Murex, an industry leader in trading, risk management and processing solutions for capital markets, announced they will run their MX.3 technology platform on Amazon Web Services, Inc. (AWS). With the acceleration of cloud adoption in capital markets, Murex and AWS agreed to collaborate to help clients migrate their Murex application workloads to the AWS Cloud. Murex clients are looking to consolidate more and more of their capital markets activity on the MX.3 platform and this means their need for infrastructure is increasing. New regulatory requirements are also driving financial organizations to use cloud to scale up their computing capacity. Murex is collaborating with AWS to meet the demand from clients to support deployment of the Murex offering on the AWS Cloud. Murex is working on the validation of a range of deployment scenarios, from using AWS Cloud for bursting grid
Darzalex®▼(daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible12.12.2017 13:33 | Pressemelding
Janssen-Cilag International NV (“Janssen”) today announced data from the Phase 3 ALCYONE study, showing Darzalex® (daratumumab) in combination with bortezomib, melphalan and prednisone (VMP) significantly improved clinical outcomes, including reducing the risk of disease progression or death by 50 percent, in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation (ASCT).1 These data were accepted as a late-breaking abstract (LBA) for presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, today at 7:30 a.m. ET (Abstract #LBA-4).1 Study findings were simultaneously published in the New England Journal of Medicine (NEJM) . 2 Daratumumab is currently indicated for use in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom